GlassScriptPhysician profile
Jared M Hu
NPI 1770023608
$30,250.88
in general payments reported to CMS, 2019-2025
27 companies · $9,525 in 2025
The $9,525 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $1,152 · 2023: $9,305 · 2024: $9,777 · 2025: $9,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $5,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,500.00 |
| Food and Beverage | $5,106.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25,094.64 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,154.14 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $590.92 | 2022-2025 | Verquvo, Capvaxive |
| Medtronic, INC. | $463.82 | 2021-2025 | Corevalve Evolut R, Micra |
| Smith+Nephew, INC. | $438.30 | 2022-2025 | Pico 7, Pico 14 |
| Astrazeneca Pharmaceuticals LP | $433.76 | 2022-2025 | Farxiga, Brilinta |
| Pfizer INC. | $401.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $356.03 | 2021-2024 | Xarelto |
| Abbott Laboratories | $261.19 | 2021-2024 | Aveir, Amplatzer Amulet |
| Sanofi-Aventis U.S. LLC | $251.62 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.82 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.82 | 2023-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $62.76 | 2023-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $58.98 | 2023-2025 | |
| Boston Scientific Corporation | $58.22 | 2022-2024 | Watchman Access System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $57.53 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $55.56 | 2022-2024 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $43.35 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $39.21 | 2024 | Nexletol |
| Shockwave Medical, INC | $35.64 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Vifor Pharma, INC. | $29.83 | 2023 | Veltassa |
| Amgen INC. | $29.39 | 2022 | |
| Philips North America LLC | $23.93 | 2024 | (5091) Amb Mon & Diag Und |
| Abiomed | $23.39 | 2024 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $23.00 | 2024 | Arcalyst |
| Cvrx, INC. | $21.72 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.